Search results for "Lymphoid malignancy"

showing 2 items of 2 documents

Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas.

2021

Diffuse large B-cell lymphoma (DLBCL) is the commonest form of lymphoid malignancy, with a prevalence of about 40% worldwide. Its classification encompasses a common form, also termed as “not otherwise specified” (NOS), and a series of variants, which are rare and at least in part related to viral agents. Over the last two decades, DLBCL-NOS, which accounts for more than 80% of the neoplasms included in the DLBCL chapter, has been the object of an increasing number of molecular studies which have led to the identification of prognostic/predictive factors that are increasingly entering daily practice. In this review, the main achievements obtained by gene expression profiling (with respect t…

0301 basic medicineOncologymedicine.medical_specialtydiagnosisdiffuse large B-cell lymphomaReviewSettore MED/08 - Anatomia Patologica03 medical and health sciences0302 clinical medicineInternal medicineDaily practicemedicineTumor MicroenvironmentHumanslcsh:QH301-705.5B celltherapybusiness.industryGene Expression ProfilingNot Otherwise SpecifiedHigh-Throughput Nucleotide SequencingGeneral Medicinemedicine.diseaseMicroarray AnalysisPrognosisLymphomaGene expression profilingdiagnosi030104 developmental biologymedicine.anatomical_structurelcsh:Biology (General)Lymphoid malignancyclassification030220 oncology & carcinogenesisnext-generation sequencingLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphomaprognosiCells
researchProduct

The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry.

2014

Our specialized population-based registry has allowed us to explore changes in incidence and survival by subtype over the last 30 years. Between 1980 and 2009, 4790 cases of lymphoid malignancies were registered using the International Classification of Diseases for Oncology. The incidence rate of lymphoid malignancies was 20.5 per 100,000 inhabitants per year, and ranged from 0.1 to 4 according to subtype. Five-year net survival was 65%, and ranged from 41% to 93% according to subtype. We observed an increase in 5-year net survival between the periods 1980-1989 and 2000-2009 (58% vs. 70%). This was observed in most but not all subtypes. Our long-standing population-based registry allowed u…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentLymphomaPopulationYoung AdultSurvival probabilityInternal medicinemedicineHumansRegistrieseducationChildNet SurvivalAgedAged 80 and overeducation.field_of_studyLeukemiabusiness.industryIncidence (epidemiology)IncidenceHematologyMiddle AgedSurvival AnalysisCancer registryOncologyLymphoid malignancyChild PreschoolHematologic NeoplasmsPopulation SurveillanceImmunologyFemaleFrancebusinessPopulation-Based RegistryInternational Classification of Diseases for OncologyFollow-Up StudiesLeukemialymphoma
researchProduct